Literature DB >> 29052610

Reply to: 'Comment on: 'One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration'.

H Almuhtaseb1,2, A Lotery1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29052610      PMCID： PMC5811726          DOI： 10.1038/eye.2017.212

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  7 in total

1.  One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration.

Authors:  H Almuhtaseb; S Kanavati; S R Rufai; A J Lotery
Journal:  Eye (Lond)       Date:  2017-02-10       Impact factor: 3.775

2.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

Authors:  Daniel F Martin; Maureen G Maguire; Stuart L Fine; Gui-shuang Ying; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Maryann Redford; Frederick L Ferris
Journal:  Ophthalmology       Date:  2012-05-01       Impact factor: 12.079

3.  First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration.

Authors:  James S Talks; Andrew J Lotery; Faruque Ghanchi; Sobha Sivaprasad; Robert L Johnston; Nishal Patel; Martin McKibbin; Clare Bailey; Sajjad Mahmood
Journal:  Ophthalmology       Date:  2015-11-12       Impact factor: 12.079

4.  Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.

Authors:  Ursula Schmidt-Erfurth; Peter K Kaiser; Jean-François Korobelnik; David M Brown; Victor Chong; Quan Dong Nguyen; Allen C Ho; Yuichiro Ogura; Christian Simader; Glenn J Jaffe; Jason S Slakter; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Olaf Sowade; Oliver Zeitz; Christiane Norenberg; Rupert Sandbrink; Jeffrey S Heier
Journal:  Ophthalmology       Date:  2013-09-29       Impact factor: 12.079

5.  Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).

Authors:  Soraya Rofagha; Robert B Bhisitkul; David S Boyer; SriniVas R Sadda; Kang Zhang
Journal:  Ophthalmology       Date:  2013-05-03       Impact factor: 12.079

6.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors:  Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2012-10-17       Impact factor: 12.079

7.  A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK.

Authors:  Philip Hykin; Usha Chakravarthy; Andrew Lotery; Martin McKibbin; Jackie Napier; Sobha Sivaprasad
Journal:  Clin Ophthalmol       Date:  2016-01-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.